Phibro Animal Health Posts Record FY2026 Sales, Guides FY2027 Above Consensus
PAHC sits 27% above its 52-week low of $28.25.
Summary
Phibro Animal Health reported Q4 FY2026 net sales of $396.7M (+5% YoY) and adjusted EPS of $0.85 (+35%), capping a record fiscal year with net sales of $1.52B (+17%) and adjusted EBITDA of $255M (+39%). The company issued FY2027 guidance for net sales of $1.55B-$1.60B and adjusted EBITDA of $258M-$268M, implying continued growth. Management also announced the closure of its Chicago Heights manufacturing facility, affecting ~100 employees, as part of a post-MFA acquisition network consolidation. The guidance assumes minimal virginiamycin sales in Brazil due to regulatory uncertainty, with potential upside if approval is secured before the phase-out period expires in about a month. This follows the 10-K filed earlier today and the CEO transition in July; the results and outlook provide a clear positive trajectory for the stock.
At the time of this announcement, PAHC was trading at $35.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $28.25 to $60.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.